Company: IMCR
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001671927-25-000006
Chunk: 194

Company: Immunocore Holdings plc
Filing Date: 2025-02-26
Form: 10-K
Item: Item 1A
Chunk 194
---
 successfully develop and commercialize our product candidates;

•failure by us to maintain our existing strategic collaborations or enter into new collaborations;

•failure by us to identify additional product candidates for our pipeline;

•failure by us or our licensors and strategic partners to prosecute, maintain, protect or enforce our intellectual property and proprietary rights;

•disputes or other developments relating to intellectual and other proprietary rights, including litigation;

•matters and our ability to obtain patent and other intellectual property protection for our technologies;

•changes in laws or regulations applicable to future products;

•an inability to obtain adequate product supply for our product candidates or the inability to do so at acceptable prices;

•the introduction of new products, services or technologies by our competitors;

•failure by us to meet or exceed financial projections we may provide to the public;

•failure by us to meet or exceed the financial projections of the investment community;

•the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community;

•changes in the structure of healthcare payment systems;

•inability to obtain adequate commercial supply for any approved product or inability to do so at acceptable prices;

•announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us, our strategic partner or our competitors;

103

Table of Contents

•inability to comply with our debt covenants and to make payments as they become due;

•additions or departures of key scientific or management personnel;

•significant lawsuits, including patent or shareholder litigation;

•changes in the market valuations of similar companies;

•general economic, industry, political and market conditions, including, but not limited to, the war in Ukraine, the conflict in the Middle East, global geopolitical tension, changes in inflation and interest rates, supply chain disruptions, and volatility in the capital markets;

•sales of our ADSs or ordinary shares by us or our shareholders in the future;

•the trading volume of our ADSs; and

•other events or factors, many of which are beyond our control.

These and other market and industry factors may cause the market price and demand for our ADSs to fluctuate substantially, regardless of our actual operating performance, which may limit or prevent investors from selling their ADSs and may otherwise negatively affect the liquidity of our ADSs. In addition, the stock market in general